EP Patent
EP2158208B1 — Process for preparing an a2a-adenosine receptor agonist and its polymorphs
Assigned to Gilead Sciences Inc · Expires 2015-04-08 · 11y expired
What this patent protects
Patent listed against regadenoson.
Drugs covered by this patent
- regadenoson (Regadenoson) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.